News (56)

NEC : Q&A(276KB) PU
NEC : Q&A (288KB) PU
NEC : Notice of Resolutions adopted at the 185th Ordinary General Meeting of Shareholders (73KB) PU
NEC : Q&A (276KB) PU
NEC : ESG Initiatives in NEC's Purpose-Driven Management (Osamu Fujikawa,Executive Vice President and CFO,Member of the Board (Representative Director), NEC Corporation)(1,088KB) PU
NEC : Q&A(399KB) PU
Transcript : NEC Corporation - Special Call
NEC : Q&A (421KB) PU
NEC : Q&A (274KB) PU
NEC : Presentation(559KB) PU
Q&A (Answer: Osamu Fujikawa, Executive Vice President and Chief Financial Officer (CFO))(260KB) PU
NEC : Q&A (281KB) PU
NEC : Notice of Resolutions adopted at the 184th Ordinary General Meeting of Shareholders PU
NEC : Q&A (525KB) PU
NEC : announces executive personnel changes PU
NEC : Development of Robust Financial and Non-financial Measurement Methodologies for Sustainable Growth (Osamu Fujikawa, Executive Vice President and CFO)(2,126KB) PU
NEC : Q&A(469KB) PU
Transcript : NEC Corporation - Special Call
Q&A (526KB) PU
CFO Message (347KB) PU
Cross-Company Corporate Strategy Promotion Framework (1,063KB) PU
NEC : Q&A (523KB) PU
Toshiba CEO Hopes to Vote on New Board Chairman by Year-End DJ
Toshiba to Appoint New Directors to Reform Corporate Governance DJ
NEC : Q&A (534KB) PU
NEC : announces executive personnel changes PU
NEC : NanoBridge Semiconductor, Inc. secures series A financing from Japan Industrial Partners and NEC for launching full-scale business PU
Transgene : NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers AQ
NEC : Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers AQ
Transgene : October 6, 2020 - Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers PU
Transgene :, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers BU
NEC : BostonGene and NEC Collaborate to Analyze Cancer Patients in Clinical Trials BU
NEC : and Siemens Partner to Provide AI Monitoring and Analysis Solution to Accelerate Digitization in Manufacturing BU
Transgene : and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers BU
NEC : and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines BU
VAXIMM : NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines EQ
NEC : Acquires Norwegian Bioinformatics Company, OncoImmunity AS BU
NEC : Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC BU
NEC : and Macromill launch consumer insight marketing business using AI PU
Transgene : to start clinical development of lead myvacTM individualized immunotherapy, TG4050, in 2019, under its partnership with NEC BU
Transgene : October 30, 2018 - NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform PU
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform BU
NEC : and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC's AI and Transgene's myvac™ platform PU
NEC : and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform BU
NEC : X appoints Dr. PG Madhavan as CXO PU
12NextSee all

Insiders



Picture Osamu Fujikawa
Osamu Fujikawa

Osamu Fujikawa currently works for NEC Corp.
as a CFO & Managing Executive Officer.




Picture Masayuki Fujikawa
Masayuki Fujikawa

Masayuki Fujikawa currently works as a Director at Bandai Visual Co., Ltd.





No results for this search